Category Archives: BioUtah News
MPF II NEXT Makes its Debut Investment in iVeena Delivery Systems
A clinical stage ophthalmology company, iVeena is developing disease-modifying therapeutics for a rare corneal disorder and an increasingly common form of nearsightedness
Utah Rep. Blake Moore Tours Logan’s BioHive Community
Yesterday, US Rep. Blake Moore (R-UT-1) visited the burgeoning BioHive community in Logan, touring Utah State University’s (USU0 state-of-the-art BioInnovations Center, Quansys Biosciences and ELITech. Utah’s life sciences industry, from Logan to St. George, is one of the fastest-growing in the nation. “Cache Valley has become a hub for bioscience, and I thank BioUtah for […]
PolarityTE Provides Update on Investigational New Drug Application
SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021. The Company received […]
Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals
NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration patient population with the appointment of Jed Fulk to the position of Vice President Sales, Government Accounts. Mr. Fulk […]
Stryker: Patient impact: our inspiration
Stryker CEO, Kevin Lobo, recently shared his thoughts about his work at Stryker and what it means to help make a difference for patients
BioHive Names Katelin Roberts Executive Director
BioHive, Utah’s collective of life sciences and healthcare innovation companies, today announced that Katelin Roberts will serve as the full time Executive Director, effective immediately.
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Recursion announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).
NIH AWARDS SINTX TECHNOLOGIES PHASE 1 GRANT FOR SN-PEEK 3D PRINTED SPINAL IMPLANTS
SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today a Phase 1 grant of $308,301 awarded by the National Institute of Health (NIH) to develop a 3-D printed, composite silicon nitride – polyetheretherketone (SN-PEEK) spinal implant.
SINTX ARMOR SHIPS FIRST ORDER AND PREPARES FOR MOVE TO UTAH
SINTX Technologies, Inc., an original equipment manufacturer of advanced ceramics, announced today that its newly created and wholly-owned subsidiary, SINTX Armor, will be located in Salt Lake City, Utah and that it has signed a 10-year lease on a facility to house development and manufacturing activities for SINTX Armor.
Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28
In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will also hold a press conference to introduce its upcoming at-home and point-of-care PCR device.
Owlet is changing the future of wearable devices
Recently, Owlet’s smart sock was used in a study of infant tachyarrhythmia, a condition where the heart beats much more rapidly than it should be for the level of exertion, reports Utah Business Magazine.
Groundbreaking Children’s Genomics Study at Intermountain Primary Children’s Hospital Provides New Options for Children to Participate
The groundbreaking HerediGene: Children’s Study – the world’s largest DNA mapping effort ever to be undertaken in kids – is now offering additional collection methods for children to participate at Intermountain Primary Children’s Hospital, including a new simple cheek swab.
